Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project
- 1 May 2007
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 31 (5), 599-604
- https://doi.org/10.1016/j.leukres.2006.07.005
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrenceCancer, 2005
- Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemiaBlood, 2005
- Expecting the Unexpected — Drug Safety, Pharmacovigilance, and the Prepared MindNew England Journal of Medicine, 2004
- Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive diseaseAnnals of Oncology, 2004
- Gemtuzumab ozogamicin in the treatment of acute myeloid leukemiaCancer, 2003
- Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantationBlood, 2003
- Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high‐risk myelodysplastic syndromesCancer, 2003
- Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basisBlood, 2003
- Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive diseaseBone Marrow Transplantation, 2002
- Experience with gemtuzumab ozogamycin (“mylotarg”) and all-trans retinoic acid in untreated acute promyelocytic leukemiaBlood, 2002